Bio-Techne Corporation (TECH)
NASDAQ: TECH · Real-Time Price · USD
72.30
-0.02 (-0.02%)
Sep 1, 2026, 10:59 AM EDT - Market open
Bio-Techne Revenue
In the fiscal year ending June 30, 2026, Bio-Techne had annual revenue of $1.22B, down -0.38%. Bio-Techne had revenue of $321.19M in the quarter ending June 30, 2026, with 1.33% growth.
Revenue (ttm)
$1.22B
Revenue Growth
-0.38%
P/S Ratio
9.33
Revenue / Employee
$405,013
Employees
3,000
Market Cap
11.34B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 1.22B | -4.60M | -0.38% |
| Jun 30, 2025 | 1.22B | 60.58M | 5.23% |
| Jun 30, 2024 | 1.16B | 22.36M | 1.97% |
| Jun 30, 2023 | 1.14B | 31.10M | 2.81% |
| Jun 30, 2022 | 1.11B | 174.57M | 18.75% |
| Jun 30, 2021 | 931.03M | 192.34M | 26.04% |
| Jun 30, 2020 | 738.69M | 24.69M | 3.46% |
| Jun 30, 2019 | 714.01M | 71.01M | 11.04% |
| Jun 30, 2018 | 642.99M | 79.99M | 14.21% |
| Jun 30, 2017 | 563.00M | 63.98M | 12.82% |
| Jun 30, 2016 | 499.02M | 46.78M | 10.34% |
| Jun 30, 2015 | 452.25M | 94.48M | 26.41% |
| Jun 30, 2014 | 357.76M | 47.19M | 15.19% |
| Jun 30, 2013 | 310.58M | -3.99M | -1.27% |
| Jun 30, 2012 | 314.56M | 24.60M | 8.48% |
| Jun 30, 2011 | 289.96M | 20.92M | 7.77% |
| Jun 30, 2010 | 269.05M | 5.09M | 1.93% |
| Jun 30, 2009 | 263.96M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioMarin Pharmaceutical | 3.41B |
| Halozyme Therapeutics | 1.66B |
| Madrigal Pharmaceuticals | 1.28B |
| Ionis Pharmaceuticals | 874.09M |
| Corcept Therapeutics | 830.81M |
| Axsome Therapeutics | 776.57M |
| Arrowhead Pharmaceuticals | 669.50M |
| Krystal Biotech | 440.48M |
TECH News
- 4 hours ago - Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals - PRNewsWire
- 7 days ago - Bio-Techne Proxy statement: Proxy filing - Filings
- 7 days ago - BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH) - GlobeNewsWire
- 12 days ago - Bio-Techne Proxy statement: Proxy filing - Filings
- 15 days ago - Bio-Techne reports Q4 adjusted EPS 52c, consensus 52c - TheFly
- 15 days ago - Bio-Techne downgraded to Equal Weight from Overweight at Wells Fargo - TheFly
- 15 days ago - Wells downgrades Bio-Techne on pending Merck KGaA buyout - TheFly
- 19 days ago - Bio-Techne Corrects Dividend Announcement - PRNewsWire